GlassScriptPhysician profile
Ethan M Gore
NPI 1003136987
$46,138.27
in general payments reported to CMS, 2019-2025
52 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,892 · 2020: $6,382 · 2021: $22K · 2022: $5,483 · 2023: $6,851 · 2024: $2,369 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,452 · Consulting Fee: $2,190 · Travel and Lodging: $285 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,452.35 |
| Consulting Fee | $2,190.00 |
| Travel and Lodging | $285.00 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,029.40 | 2020-2025 | |
| Biogen, INC. | $11,169.29 | 2020-2024 | Vumerity, Tysabri, Spinraza |
| Allergan, INC. | $6,755.11 | 2019-2022 | |
| Eisai INC. | $4,301.27 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $904.83 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $862.76 | 2019-2024 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $727.57 | 2020-2025 | Xcopri |
| Mdd US Operations, LLC | $672.72 | 2019-2025 | Gocovri |
| Pfizer INC. | $572.15 | 2023-2025 | |
| Amgen INC. | $430.57 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $370.24 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $360.44 | 2019-2024 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $343.01 | 2019-2020 | |
| Ucb, INC. | $328.42 | 2019-2024 | Nayzilam, Briviact, Rystiggo |
| Lundbeck LLC | $262.95 | 2019-2025 | Vyepti, Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.